发明名称 NEW USE OF L-HISTIDINE AND DERIVATIVES THEREOF
摘要 The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered a s a single oral dose comprised from 0.2-20 g.
申请公布号 US2014155449(A1) 申请公布日期 2014.06.05
申请号 US201214235128 申请日期 2012.07.24
申请人 Zsolt Baranyai;Brücher Ernö;Bussi Simona;Maiocchi Alessandro;Uggeri Fulvio 发明人 Zsolt Baranyai;Brücher Ernö;Bussi Simona;Maiocchi Alessandro;Uggeri Fulvio
分类号 A61K31/4172;A61K31/28 主分类号 A61K31/4172
代理机构 代理人
主权项 1. A method of preventing Gadolinium (Gd3+) accumulation in a patient's target organ after a GDBCA (Gadolinium Based Contrast Agent) administration comprising: administering L-Histidine or a derivative thereof before or simultaneous with administration of a GDBCA (Gadolinium Based Contrast Agent).
地址 Debrecen HU